Labcorp reports Q4 adjusted EPS $3.45, consensus $3.39

Reports Q4 revenue $3.33B, consensus $3.31B. “In 2024, Labcorp (LH) delivered exceptional results driven by both organic and inorganic growth,” said Adam Schechter, chairman and CEO of Labcorp. “We announced 10 transactions to further establish our position as a trusted partner to hospitals, health systems and regional/local laboratories. Additionally, we strengthened our presence in key high growth areas including oncology, women’s health, neurology and autoimmune disease. In 2025, we are positioned to deliver strong growth and margin expansion across both Diagnostics Laboratories and Biopharma Laboratory Services, while we improve health and improve lives of patients around the world.”